Welcome to our dedicated page for Adc Therapeutics Sa news (Ticker: ADCT), a resource for investors and traders seeking the latest updates and insights on Adc Therapeutics Sa stock.
ADC Therapeutics SA (NYSE: ADCT) is a commercial-stage oncology company focused on antibody drug conjugates, and its news flow centers on clinical progress, regulatory developments, and corporate updates. The company’s primary product, ZYNLONTA (loncastuximab tesirine-lpyl), is a CD19-directed ADC approved under accelerated and conditional pathways for certain adults with relapsed or refractory diffuse large B-cell lymphoma after at least two prior systemic therapies.
News about ADCT commonly includes updates from its LOTIS clinical program, such as the Phase 3 LOTIS-5 trial of ZYNLONTA plus rituximab in second-line or later DLBCL and the Phase 1b LOTIS-7 trial evaluating ZYNLONTA in combination with bispecific antibodies and other agents in B-cell non-Hodgkin lymphoma. Company releases have highlighted response rates, safety findings, and enrollment milestones from LOTIS-7, as well as anticipated timelines for sharing full data and pursuing regulatory and compendia strategies.
Investors and followers of ADCT news will also find announcements on preliminary revenue and cash estimates, participation in healthcare conferences, and equity-related actions such as employee inducement grants and private placements. These items appear in both press releases and related Form 8-K filings, giving context on the company’s commercial performance and financing plans alongside its clinical pipeline.
This news page aggregates such disclosures so readers can track ADCT’s key events, from clinical trial readouts and investigator-initiated study updates in indolent lymphomas to progress on its early-stage PSMA-targeting ADC. For those monitoring ADCT stock, revisiting this page provides a consolidated view of the company’s evolving clinical, regulatory, and corporate narrative.
ADC Therapeutics has announced the validation of its Marketing Authorization Application (MAA) for ZYNLONTA by the European Medicines Agency (EMA). This pivotal application is supported by data from the LOTIS-2 trial, which demonstrated an overall response rate of 48.3% in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The FDA had previously granted accelerated approval for ZYNLONTA in 2021. This validation marks an essential step towards making ZYNLONTA available to European patients in need.
ADC Therapeutics (NYSE: ADCT) announced a conference call on November 2, 2021, at 8:30 a.m. EDT to discuss its third quarter 2021 financial results and provide business updates. The company, which focuses on antibody drug conjugates for cancer treatment, highlights its FDA-approved ADC ZYNLONTA for relapsed or refractory diffuse large B-cell lymphoma. Additionally, the ADC Cami is undergoing late-stage trials for Hodgkin lymphoma. The call can be accessed via phone or through a live webcast on the company’s investor relations website.
Overland ADCT BioPharma has commenced a pivotal Phase 2 clinical trial in China, dosing the first patient with ZYNLONTA® for relapsed or refractory diffuse large B-cell lymphoma. Following its FDA accelerated approval in April 2021, ZYNLONTA stands as the first CD19-targeted antibody drug conjugate for adult patients post multiple systemic therapies. This trial aims to validate ZYNLONTA's efficacy and safety, facilitating its potential registration in China. Overland ADCT is committed to addressing the unmet medical need for patients with r/r DLBCL in Asia.
ADC Therapeutics (NYSE: ADCT) has initiated a Phase 1 clinical trial for ADCT-901, targeting KAAG1, a novel tumor antigen in advanced solid tumors with high unmet needs. The trial, focused on safety, tolerability, pharmacokinetics, and antitumor activity, follows FDA's clearance of the IND application. KAAG1 is significantly expressed in tumors like ovarian and triple-negative breast cancer, presenting a potential therapeutic opportunity.
ADC Therapeutics (NYSE: ADCT) announces CEO Chris Martin's participation in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Thursday, September 30, at 9:20 a.m. ET. A live webcast will be accessible on the company's Investors page, with a replay available for 30 days. ADC Therapeutics focuses on developing targeted antibody drug conjugates (ADCs) for cancer treatment, with its CD19-directed ADC ZYNLONTA® approved by the FDA for relapsed diffuse large B-cell lymphoma. The company also has other ADCs in clinical and preclinical development.
ADC Therapeutics has received Orphan Drug Designation from the European Commission for ZYNLONTA®, a CD19-targeted antibody drug conjugate (ADC) aimed at treating diffuse large B-cell lymphoma (DLBCL). This designation highlights the significant unmet medical need within the EU for DLBCL patients. Should ZYNLONTA be approved, it will enjoy ten years of marketing exclusivity and various incentives. The FDA-approved ZYNLONTA has shown promising clinical trial results, with an overall response rate of 48.3% for patients after two or more lines of therapy.
ADC Therapeutics (NYSE: ADCT) has announced that Chief Medical Officer Joseph Camardo and Chief Commercial Officer Jennifer Herron will participate in a fireside chat at Morgan Stanley’s 19th Annual Global Healthcare Conference on September 14 at 8:45 a.m. ET. Investors can access a live webcast and replay through the company's website for 30 days. ADC Therapeutics focuses on innovative antibody drug conjugates (ADCs) aimed at treating cancer, including their FDA-approved ZYNLONTA® for specific lymphoma treatments.
ADC Therapeutics (NYSE: ADCT) announced the departure of Chief Medical Officer Jay Feingold, who is leaving to pursue a new opportunity. He played a crucial role in the growth of the company, particularly in the development of ZYNLONTA, its first commercial therapy. Joseph Camardo has been appointed as the new Chief Medical Officer, bringing extensive experience from previous roles at Celgene and Wyeth. Camardo's leadership is expected to ensure continuity in clinical development as the company advances its proprietary antibody drug conjugates for treating cancer.
ADC Therapeutics (ADCT) announced a $325 million royalty purchase agreement with HealthCare Royalty Partners. This deal includes $225 million upon closing and up to $100 million in future milestone payments for ZYNLONTA™ and Cami. ADCT will pay a 7% royalty on net sales from ZYNLONTA and Cami, with a cap of 2.25x to 2.50x the amount received. Proceeds will support further development and commercialization of these therapies, enhancing ADCT's financial position.
ADC Therapeutics (NYSE: ADCT) reported its Q2 2021 financial results, highlighting accelerated FDA approval for ZYNLONTA™ and net sales of $3.8 million since the April launch. R&D expenses rose to $39.5 million due to commercial preparations, while sales and marketing expenses increased to $15.2 million. The net loss decreased to $72.6 million, or $0.95 per share, compared to $126.6 million in Q2 2020. Positive trial results and upcoming milestones for ZYNLONTA were noted, along with ongoing efforts for geographic expansion and further clinical studies.